Yabao Pharmaceutical Group Co. Ltd. Class A

Yabao Pharmaceutical Group Co. Ltd. Class A

SSSE:600351
6.61
CNY
+0.13
(+2.01%)
0.52EPS
13.06P/E
4.72BMarket Cap
Yabao Pharmaceutical Group Co. Ltd. Class A
SSE:600351
(Shanghai Stock Exchange)

Recent

price

6.61

P/E

ratio

13.06

div

yld

8.37%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.88
2.59
1.92
2.34
2.78
2.98
2.29
3.25
3.72
4.37
3.39
3.55
3.64
3.79
3.76
3.22
3.17
Revenue per Share
0.23
0.29
0.17
0.17
0.25
0.32
0.03
0.25
0.35
0.02
0.14
0.24
0.14
0.26
0.34
0.46
0.52
Basic EPS, GAAP
-0.27
-0.12
-0.31
-0.06
0.01
0.06
0.09
0.08
0.46
0.39
0.41
0.44
0.53
0.52
0.61
0.75
- -
Free Cash Flow per Basic Share
0.08
0.14
0.08
0.12
0.14
0.24
0.14
0.07
0.14
0.35
0.06
0.08
0.11
0.07
0.16
0.3
0.55
Dividend per Share
1.56
1.8
2.31
2.43
2.62
3.41
3.33
3.57
3.69
3.49
3.61
3.8
3.86
3.87
4.02
4.17
3.98
Book Value per Share
1.13
1.36
1.92
2.14
2.37
3.17
2.63
2.87
2.98
3.06
3.14
3.31
3.39
3.43
3.59
3.81
3.61
Tangible Book Value per Share
627
643
661
695
680
692
787
787
785
695
767
780
748
768
714
696
692
Basic Weighted Avg Shares
1,182
1,663
1,267
1,625
1,890
2,066
1,806
2,559
2,918
3,042
2,602
2,764
2,718
2,910
2,686
2,240
2,195
Sales/Revenue/Turnover
15.51
17.57
11.34
8.37
12.16
12.78
-1.68
11.1
12.93
12.96
6.22
8.11
7.89
11.19
12.63
15.61
17.74
Operating Margin (%)
51
74
90
93
126
135
158
175
171
173
170
171
164
159
141
137
- -
Depreciation Expense
144
186
112
118
170
222
23
200
273
14
107
187
105
200
243
320
362
Net Income, GAAP
14.35
18.22
14.85
12.97
13.13
12.02
2.8
11.07
13.92
78.35
14.47
8.84
16.75
17.84
23.34
19.91
19.33
Effective Tax Rate (%)
12.21
11.21
8.87
7.27
9
10.75
1.25
7.83
9.37
0.46
4.13
6.77
3.85
6.86
9.04
14.29
16.47
Profit Margin (%)
152
-100
127
65
-92
639
261
462
653
595
622
792
914
968
977
1,193
1,105
Working Capital
301
67
93
133
109
79
47
20
20
20
24
32
7
3
2
36
2
LT Debt
1,003
1,159
1,615
1,696
1,820
2,678
2,730
2,914
3,017
2,724
2,818
2,964
3,007
2,993
2,895
2,825
2,698
Total Equity
8.32
10.38
3.52
2.97
5.87
6.26
-0.09
5.4
7.15
0.29
3.05
5.33
2.96
5.59
7.46
10.19
- -
Return on Invested Capital (%)
10.99
11.88
7.22
6.26
8.17
8.76
1.41
6.37
7.52
0.73
3.76
6.04
3.46
6.9
8.58
11.66
- -
Return on Capital (%)
15.52
17.53
8.19
7.2
9.73
9.89
0.85
7.37
9.57
0.5
3.93
6.56
3.55
6.71
8.27
11.08
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
2
2
LT Borrowings
35
35
- -
LT Finance Leases
1
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
692
692
692
Market Capitalization
4,616
3,979
4,719

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,604
1,602
1,548
Cash, Cash Equivalents & STI
867
925
918
Accounts Receivable, Net
208
202
192
Inventories
294
274
286
Total Current Liabilities
410
421
442
Payables & Accruals
- -
- -
- -
ST Debt
1
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.64%
0.09%
-2.41%
Free Cash Flow
58.04%
10.76%
20.11%
Net Income, GAAP
148.71%
34.87%
31.86%
Sales/Revenue/Turnover
2.02%
-2.54%
-16.6%
Total Cash Common Dividend
27.22%
45.61%
86.57%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
771
672
678
565
2,686
2025
615
525
- -
531
2,240
2026
572
573
518
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.09
0.08
0.01
0.34
2025
0.15
0.1
- -
0.15
0.46
2026
0.15
0.1
0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
- -
- -
0.16
2025
- -
0.3
- -
- -
0.3
2026
0.2
0.15
0.2
- -
- -
Business
Yabao Pharmaceutical Group Co., Ltd. (600351.SS) researches, develops, manufactures and sells Chinese and Western medicines, active pharmaceutical ingredients, pharmaceutical packaging materials and health products primarily in China and select international markets; its core offerings encompass pediatric products such as Ding Guier umbilical patch, barley bud spleen-strengthening gel and children's throat cleansing antipyretic oral solution; cardiovascular and cerebrovascular medicines including Zhenju antihypertensive tablets, nimodipine tablets and betahistine hydrochloride injections; endocrine treatments like nifedipine sustained-release tablets, lipoic acid tablets and thioctic acid injections; women's health solutions such as gynosteine dispersible tablets; general health items including vitamin C effervescent tablets and zinc gluconate oral solution; and dosage forms spanning light pastes, tablets, injections, capsules and oral liquids. Founded in 1978 and headquartered in Yuncheng, Shanxi Province, China, at No. 1 Gongye Boulevard, Fenglingdu Economic Development Zone, the company operates through multiple subsidiaries and branches with over 3,600 employees, focusing on chronic disease treatments for the elderly, women and children while maintaining a robust R&D pipeline in innovative traditional Chinese medicines, modified new drugs and pediatric therapies. In recent developments, Yabao Pharmaceutical Group signed a technology transfer agreement for a new Chinese medicine project, obtained clinical trial approval for new indications of the SY-005 project, terminated the long-term SY-009 Type 2 diabetes oral drug development after investing CNY 87.9 million and announced impairment preparations, released its 2025 semi-annual report, reduced registered capital, repurchased shares including 2 million shares for CNY 13.27 million from October to November 2025, and plans to sell 62% equity in a subsidiary expected to boost 2025 total profit by CNY 59 million. The company sustains ongoing R&D in diabetes and lipid-lowering areas with products like Sitagliptin Metformin Extended-Release Tablets, Alogliptin Benzoate Tablets, Gynostemma Pentaphyllum Total Glycosides Dispersible Tablets and pipelines including Ezetimibe Tablets and Trelagliptin Tablets, alongside prior strategic partnerships such as with Lupin in 2022 for pediatric formulations.